


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-23 (Cancelled).

24. (Previously Presented) A compound comprising the following structural formula:



or pharmaceutically acceptable salts thereof, wherein Ph is a phenyl group.

25. (Previously Presented) The compound of Claim 24, having a  $K_i$  of less than or equal to  $10^{-6}$  M for memapsin 2.

26. (Previously Presented) The compound of Claim 25, having a  $K_i$  of less than or equal to 2 nM for memapsin 2.

27. (Currently Amended) The compound of Claim 26, having a  $K_i$  of less than or equal to + 1.6 nM for memapsin 2.

28. (Previously Presented) The compound of Claim 24, which is permeable to the blood brain barrier.

29. (Previously Presented) The compound of Claim 24, which blocks cleavage by memapsin 2 of amyloid precursor protein under physiological conditions.


30. (Previously Presented) A method for treating a patient to decrease the likelihood of developing or the progression of Alzheimer's disease comprising administering to the patient an effective amount of a compound of Claim 24.

31. (Previously Presented) The method of Claim 30, wherein the inhibitor is administered orally.

32. (Previously Presented) The method of Claim 30, wherein the inhibitor blocks cleavage of amyloid precursor protein.


33. (Withdrawn) A method of preparing a Leu\* Ala dipeptide isostere, comprising the steps of:

a) reacting ethyl propiolate and N-(tert-butoxycarbonyl)-leucinal in the presence of n-butyl lithium or lithium diisopropyl amine to form ethyl-5-((tert-butoxycarbonyl)amino)-4-hydroxy-7-methyloct-2-ynoate represented by the following structural formula:




b) reacting the ethyl-5-{{tert-butoxycarbonyl}amino}-4-hydroxy-7-methyloct-2-ynoate with hydrogen in the presence of Pd/BaSO<sub>4</sub> to form an intermediate;


c) reacting the intermediate with an acid to form 5-{1'-{{tert-butoxycarbonyl}amino}-3'-methylbutyl}-dihydrofuran-2(3H)-one represented by the following structural formula:



d) reacting iodomethane with 5-{1'-{{tert-butoxycarbonyl}amino}-3'-methylbutyl}-dihydrofuran-2(3H)-one in the presence of hexamethyldisilazane to form 5-{1'-{{tert-butoxycarbonyl}amino}-3'-methylbutyl}-3-methyl-dihydrofuran-2(3H)-one represented by the following structural formula:




e) reacting 5-{1'-{{tert-butoxycarbonyl}amino}-3'-methylbutyl}-3-methyl-dihydrofuran-2(3H)-one with a base to form a Leu\* Ala dipeptide isostere represented by the following structural formula:




34. (Withdrawn) The method of Claim 33, further comprising the steps of:

a) reacting N-(tert-butoxycarbonyl)-leucine with N,O-dimethylhydroxyamine hydrochloride in the presence of an aprotic base to form N-(tert-butoxycarbonyl)-leucine-N'-methoxy-N'-methylamide represented by the following structural formula:




; and


b) reacting N-(tert-butoxycarbonyl)-leucine-N'-methoxy-N'-methylamide with lithium aluminum hydride to form N-(tert-butoxycarbonyl)-leucinal represented by the following structural formula:




35. (Withdrawn) The method of Claim 33, further comprising the step of reacting the Leu\* Ala dipeptide isostere with tert-butyldimethylchlorosilane in the presence of a base to form a hydroxy protected Leu\*Ala dipeptide isostere represented by the following structural formula:



36. (Withdrawn) The method of Claim 35, further comprising the step of reacting the Leu\* Ala dipeptide isostere with tert-butyldimethylchlorosilane in the presence of a base to form a hydroxy protected Leu\*Ala dipeptide isostere represented by the following structural formula:




37. (Withdrawn) The method of Claim 36, further comprising the steps of:  
a) treating the hydroxy protected Leu\* Ala dipeptide isostere with an acid to form a Leu\* Ala dipeptide isostere having a deprotected amine group represented by the following structural formula:




; and

b) reacting the amine deprotected Leu\* Ala dipeptide isostere with N-(9-fluorenylmethoxycarbonyl-succinimide (Fmoc) in the presence of a base to form an Fmoc protected Leu\* Ala dipeptide isostere represented by the following structural formula:



38. (Withdrawn) The method of Claim 37, further comprising the steps of:

a) treating the hydroxy protected Leu\* Ala dipeptide isostere with an acid to form a Leu\* Ala dipeptide isostere having a deprotected amine group represented by the following structural formula:



b) reacting the amine deprotected Leu\* Ala dipeptide isostere with N-(9-fluorenylmethoxycarbonyl-succinimide (Fmoc) in the presence of a base to form an Fmoc protected Leu\* Ala dipeptide isostere represented by the following structural formula:

